PROTAC targeted protein degraders: the past is prologue

Nature Reviews Drug Discovery, Journal Year: 2022, Volume and Issue: 21(3), P. 181 - 200

Published: Jan. 18, 2022

Language: Английский

---

RNA in cancer

Nature reviews. Cancer, Journal Year: 2020, Volume and Issue: 21(1), P. 22 - 36

Published: Oct. 20, 2020

Language: Английский

---

Targeted protein degradation: expanding the toolbox

Nature Reviews Drug Discovery, Journal Year: 2019, Volume and Issue: 18(12), P. 949 - 963

Published: Oct. 30, 2019

Language: Английский

---

Roles and mechanisms of alternative splicing in cancer — implications for care

Nature Reviews Clinical Oncology, Journal Year: 2020, Volume and Issue: 17(8), P. 457 - 474

Published: April 17, 2020

Language: Английский

---

Advancing targeted protein degradation for cancer therapy

Nature reviews. Cancer, Journal Year: 2021, Volume and Issue: 21(10), P. 638 - 654

Published: June 15, 2021

Language: Английский

---

Development of targeted protein degradation therapeutics

Nature Chemical Biology, Journal Year: 2019, Volume and Issue: 15(10), P. 937 - 944

Published: Sept. 16, 2019

Language: Английский

---

Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16

Nature Chemical Biology, Journal Year: 2019, Volume and Issue: 15(7), P. 737 - 746

Published: June 17, 2019

Language: Английский

---

PROTACs: An Emerging Therapeutic Modality in Precision Medicine

Cell chemical biology, Journal Year: 2020, Volume and Issue: 27(8), P. 998 - 1014

Published: Aug. 1, 2020

Language: Английский

---

Alternative‐splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics

Wiley Interdisciplinary Reviews - RNA, Journal Year: 2018, Volume and Issue: 9(4)

Published: April 25, 2018

Defects in alternative splicing are frequently found human tumors and result either from mutations splicing‐regulatory elements of specific cancer genes or changes the regulatory machinery. RNA regulators have emerged as a new class oncoproteins tumor suppressors, contribute to disease progression by modulating isoforms involved hallmark pathways. Thus, dysregulation is fundamental provides potentially rich source novel therapeutic targets. Here, we review alterations factors detected tumors, well resulting alternatively spliced that impact hallmarks, discuss how they pathogenesis. highly regulated process and, such, themselves tightly regulated. Differential transcriptional posttranscriptional regulation modulates their levels activities cells. Furthermore, composition microenvironment can also influence which expressed given cell type drug responses. Finally, summarize current efforts targeting splicing, including global inhibition using small molecules blocking spliceosome splicing‐factor‐modifying enzymes, splice‐switching RNA‐based therapeutics modulate cancer‐specific isoforms. This article categorized under: Disease Development > Processing Splicing Regulation/Alternative

Language: Английский

---

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

Nature, Journal Year: 2020, Volume and Issue: 585(7824), P. 293 - 297

Published: June 3, 2020

Language: Английский

---